Status:
COMPLETED
Novel Lung Functional Imaging for Personalized Radiotherapy
Lead Sponsor:
University of California, Davis
Conditions:
Lung Cancer
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The primary objective of this study is to assess the safety and feasibility of personalized radiotherapy with four-dimensional (4D) computed tomography (CT)-based pulmonary ventilation imaging, which ...
Detailed Description
In this clinical trial, the investigators will assess the safety and feasibility of 4D CT ventilation image-guided personalized radiotherapy. The investigators will deliver personalized radiotherapy t...
Eligibility Criteria
Inclusion
- Primary lung cancer or metastatic disease to the lungs to be treated with either conventionally-fractionated radiotherapy (CFRT) or hypo-fractionated stereotactic ablative radiotherapy (SABR).
- Age restriction and/or gender/ethnic restrictions: Patients must be ≥18 years of age. There are no gender or ethnic restrictions.
- Concurrent chemotherapy is allowed, but not required.
- Life expectancy with treatment should be ≥6 months in the estimation of the treating physicians.
- Zubrod performance status ≤2
- Adequate marrow and hepatic function defined as Hgb ≥8; platelets ≥100k; ANC≥1500; LFTs ≤2x upper limit of normal and creatinine ≤1.3 or creatinine clearance of ≥50
- Patient must be able to provide study specific informed consent prior to study entry.
Exclusion
- Prior radiotherapy for thoracic cancer or other malignancy leading to any overlap of planned radiotherapy fields.
- For patients undergoing definitive CFRT, patients with distant metastatic disease are not eligible.
- For patients undergoing SABR, both early stage primary lung cancer patients and those with limited metastatic disease to the lungs are eligible; however, patients with oligometastatic disease should have a controlled primary and no more than one other involved organ system.
- Children (\<18 years of age), pregnant women, University of California employees or students, or prisoners will be excluded from this study.
Key Trial Info
Start Date :
September 15 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 19 2021
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT02308709
Start Date
September 15 2014
End Date
November 19 2021
Last Update
November 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California Davis Medical Center
Sacramento, California, United States, 95817